
Aprea Accelerates APR-1051 Trial; Q2 Net Loss $3.6M
Aprea Therapeutics reported its second-quarter 2026 financial results and provided a business update, highlighting accelerated enrollment in its Phase 1 ACESOT-1051 trial for oral WEE1 inhibitor APR-1051. The company is expanding the trial to include uterine serous carcinoma and Cyclin E–overexpressing platinum-resistant ovarian cancer, and evaluating combination regimens. Early single-agent activity for APR-1051 was observed, including partial responses. Aprea ended the quarter with $41.2 million in cash and cash equivalents, extending its cash runway into Q1 2028.
Key Highlights
- Enrollment in Phase 1 APR-1051 trial accelerating, expanding to 10 active sites.
- Trial expanded to include 50+ patients with uterine serous carcinoma or platinum-resistant ovarian cancer.
- Updated Phase 1 data showed early single-agent activity for APR-1051, including partial responses.
- Cash and cash equivalents totaled $41.2 million as of June 30, 2026.
- Cash runway extended into the first quarter of 2028.
- Q2 2026 operating loss was $4.0 million, compared to $3.4 million in Q2 2025.
- Q2 2026 net loss was $3.6 million, or $(0.07) per share.
- R&D expenses increased to $2.5 million in Q2 2026 from $1.9 million in Q2 2025.
Price Impact
More from APRE
Aprea Therapeutics Reports Positive Interim Data for APR-1051 Trial
Aprea Therapeutics Q3 Net Loss Widens to $4.81M; Cash Funds Operations into 2028
Aprea Therapeutics Reports Q3 2026 Results; Cash Runway to Q1 2028